Yesterday the FDA’s advisory committee recommended four peptides for compounding access on a series of close votes. Today they finished the job on the last three, and for the first time all week, they told the FDA no on one of them.
Here is what happened on day two, and what it adds to the picture.
Friday’s results
The Pharmacy Compounding Advisory Committee, the same panel from Thursday, voted on the remaining three peptides nominated for the Section 503A Bulk Drug Substances List. That is the list that determines what a compounding pharmacy is allowed to work with. The results split:
- Semax, nominated for migraines and two neurological conditions, cerebral ischemia and trigeminal neuralgia, passed 8 to 5.
- Epitalon, nominated for insomnia, passed 7 to 4.
- Emideltide, also called DSIP, nominated for opioid withdrawal, chronic insomnia, and narcolepsy, failed 6 to 7.
So across the full two days, the committee recommended six of the seven peptides and rejected one. The rejection is the part worth paying attention to.
Why the one rejection actually matters
It would have been easy to read Thursday’s four straight yes votes as a panel that had already made up its mind and was going to wave everything through. Today’s emideltide vote says otherwise.
The margin was a single vote, 6 to 7, so this was not a landslide against it. But the committee was willing to draw a line, and where they drew it is telling. Emideltide’s proposed uses include opioid withdrawal and narcolepsy, which are serious conditions with real downstream risk if the treatment is wrong. David Pope, a pharmacy officer on the panel, broke from the group specifically over what he called potentially dangerous downstream consequences.
That is a committee weighing risk by indication, not just voting on the molecule in the abstract. I find that more reassuring than four easy yes votes would have been. It suggests the panel was actually thinking.
Where semax stands
Semax is the one I get asked about most, so it is worth a closer look. It passed, 8 to 5.
Part of why it cleared is that semax has more of a track record than most peptides in this conversation. It has been used and studied in Russia for years, which gives it a longer paper trail than something like KPV that has essentially no human data. Supporters on the panel leaned on that.
The FDA’s own reviewers were less impressed. They found the evidence insufficient for the specific uses on the table. That gap, between a compound having history and a compound having the kind of controlled data US regulators want, ran through this entire two-day meeting. Semax is a cleaner example of it than most.
The FDA still said no to everything
This is the thread that ties both days together and it keeps getting lost in the coverage. The FDA’s staff recommended against all seven peptides in their briefing documents. Not the ones that failed. All of them, including the six the committee ended up endorsing.
Mary Thanh Hai, who directs the FDA’s Office of New Drugs, put the agency’s core worry plainly when she talked about the difference between a regulated product and what is floating around now. In the grey market, she said, testing is not a requirement to be sent to us. In other words, the FDA cannot vouch for what it never sees.
That is the same concern that came up Thursday about identity and consistency, and it is the concern I think patients should actually internalize, separate from how any single vote went.
What this changes right now
Nothing, and I want to keep being clear about that because the headlines are running ahead of the facts.
A committee recommendation is advice to the FDA, not a decision. The FDA can accept it or not, and here the agency’s own staff took the opposite position from the panel on every peptide. Even for the six that passed, actually adding them to the 503A list requires formal notice-and-comment rulemaking: a proposed rule, a public comment window, and a final rule. That is a process measured in a year or more, not days.
So as of tonight, what a compounding pharmacy can legally make is exactly what it could make on Wednesday. If anyone tries to sell you something this weekend on the strength of these votes, they are selling ahead of the rules.
How this fits what we do
Our approach does not move on a committee vote, and it did not move today.
What we care about is the same thing the FDA kept pointing at from the other direction: knowing what is actually in the vial. Every peptide we use carries a batch-specific certificate of analysis from an independent lab, covering identity and purity by HPLC, endotoxin testing to USP standards, heavy metals, and sterility. Paired with baseline labs where they are indicated, a protocol that has a defined start and stop, and follow-up to judge honestly whether something is helping. That is true for semax and for the peptides that came up Thursday like BPC-157.
What today reinforced, if anything, is the case against the untested end of the market. The panel just spent two days wrestling with whether these compounds can be made to a consistent standard at all. A vial from an anonymous online seller has none of that scrutiny and no documentation to check. That is the risk, not the peptide itself.
If you are on peptides now, from us or from anywhere, and you want a straight conversation about what you are taking, that is worth an appointment. Call us at (727) 274-1972 or book online at olympiaaesthetics.com/contact/. You can read our full breakdown of Thursday’s votes here, and more about our peptide therapy programs here.
This post covers a regulatory development and is general information, not medical advice. Peptide therapy is not appropriate for everyone. Individual candidacy is determined during a medical consultation.
